Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMedOpen access

Maximizing the Longevity and Volume Retention of Fat Grafts: Advances in Clinical Practice.

Acharya P., Mohammed C., Desai A., Rojas Gomez MC., Sunil G., Duran S PX.

Narrative Review on Face & Skin, published in Cureus (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Cureus (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
40851734
PMCID
PMC12368828
DOI
10.7759/cureus.88493
Citations
1

Abstract (original English)

Autologous fat grafting (AFG) is increasingly utilized in aesthetic and reconstructive surgery owing to its biocompatibility, regenerative properties, and ease of harvest. However, inconsistent graft retention rates pose a persistent clinical challenge. This review explores contemporary advancements aimed at improving fat graft survival and volume retention. Biological enhancements, such as platelet-rich plasma (PRP), stromal vascular fraction (SVF), and adipose-derived stem cells (AdSCs), have demonstrated efficacy in promoting angiogenesis, reducing fibrosis, and improving graft integration. Emerging strategies, including vitamin E (VE) augmentation, compact fat grafting, and soluble molecule preconditioning with agents like deferoxamine (DFX) and vascular endothelial growth factor (VEGF), have shown promise in experimental and clinical models. The synergistic use of PRP and AdSCs yields higher growth factor expression, enhancing tissue viability. Innovations like Botulinum Toxin-A (BoNTA) for muscle immobilization, concentrated de-oiled fat (CDF), and biodegradable scaffolds further contribute to improved outcomes. Site-specific adaptations - for craniofacial, breast, and gluteal regions - demonstrate tailored approaches that enhance regional graft viability. Despite these advancements, standardization remains a barrier due to methodological heterogeneity in harvesting, proc

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research